SCHEDULE: Highbridge Capital Management Discloses 7.1% Stake in Plus Therapeutics

Highbridge Capital Management, LLC has reported beneficial ownership of 7.1% of Plus Therapeutics, Inc. common stock, primarily through the exercise of warrants.

Summary

• Highbridge Capital Management, LLC (Highbridge) has filed a Schedule 13G, indicating beneficial ownership of 13,157,894 shares of Plus Therapeutics, Inc. common stock.
• This represents 7.1% of the total outstanding common stock as of March 18, 2026.
• The reported shares are issuable upon the exercise of warrants held by Highbridge Funds.
• Highbridge Capital Management, LLC is an investment adviser to these funds.
• The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports ownership changes rather than company performance or strategic shifts. The significance lies in the investor's action, not necessarily in new company information.

Positives

• Highbridge Capital Management, LLC, a significant investment entity, has taken a notable position in Plus Therapeutics, Inc., potentially signaling confidence in the company's future prospects.
• The ownership stake of 7.1% is substantial and could lead to increased investor interest and liquidity for the stock.

Negatives

• The filing does not provide specific financial performance data for Plus Therapeutics, Inc., making it difficult to assess the company's current operational health.
• The ownership is based on the exercise of warrants, which implies a contingent claim on shares rather than direct ownership of existing stock.

Risks

• The value of the reported shares is contingent on the exercise of warrants, which may be subject to specific terms and conditions.
• The filing does not detail any specific risks associated with Plus Therapeutics, Inc. itself, focusing solely on Highbridge's ownership status.

Future Outlook

The filing does not contain forward-looking statements or guidance from Plus Therapeutics, Inc. It solely reports on the ownership stake of Highbridge Capital Management, LLC.

Industry Context

StockSavvy.ai notes that significant stake acquisitions by investment managers, especially through warrant exercises, can be a signal of potential future strategic interest or a belief in undervaluation within the biotechnology or pharmaceutical sectors, where Plus Therapeutics, Inc. operates.

Stakeholder Impact

• Shareholders of Plus Therapeutics, Inc. may see increased attention on the stock due to the significant stake held by Highbridge Capital Management, potentially impacting liquidity and share price.
• The investment by Highbridge could be interpreted as a positive signal by other investors, potentially attracting further investment.

Next Steps

• Monitor future filings from Highbridge Capital Management, LLC for any changes in their stake in Plus Therapeutics, Inc.
• Observe any potential strategic actions or communications from Plus Therapeutics, Inc. that may be influenced by this significant ownership.

Key Dates

Keywords

Plus Therapeutics, Highbridge Capital Management, Schedule 13G, Warrants, Beneficial Ownership, SEC Filing, Investment Adviser, Common Stock